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Molecular modelingfﬁnity labeling, and docking and molecular dynamics were used to characterize
the tricyclic antidepressant (TCA) binding sites in the nicotinic acetylcholine receptor (nAChR). Competition
experiments indicate that the noncompetitive antagonist phencyclidine (PCP) inhibits [3H]imipramine
binding to resting (closed) and desensitized nAChRs. [3H]2-azidoimipramine photoincorporates into each
subunit from the desensitized nAChR with ∼25% of the labeling speciﬁcally inhibited by TCP (a PCP analog),
whereas no TCP-inhibitable labeling was observed in the resting (closed) state. For the desensitized nAChR
and within the α subunit, the majority of speciﬁc [3H]2-azidoimipramine labeling mapped to a ∼20 kDa
Staphylococcus aureus V8 protease fragment (αV8-20; Ser173-Glu338). To further map the labeling site, the
αV8-20 fragment was further digested with endoproteinase Lys-C and resolved by Tricine SDS-PAGE. The
principal labeled fragment (11 kDa) was further puriﬁed by rpHPLC and subjected to N-terminal sequencing.
Based on the amino terminus (αMet243) and apparent molecular weight, the 11 kDa fragment contains the
channel lining M2 segment. Finally, docking and molecular dynamics results indicate that imipramine and
PCP interact preferably with the M2 transmembrane segments in the middle of the ion channel. Collectively,
these results are consistent with a model where PCP and TCA bind to overlapping sites within the lumen of
the Torpedo nAChR ion channel.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionThe main pharmacological action of antidepressants (ADs) is to
increase the synaptic concentrations of norepinephrine, serotonin,
and/or dopamine by inhibiting the reuptake of these neurotransmit-
ters from the synaptic cleft. Moreover, additional studies have shown
that ADs act as noncompetitive antagonists (NCAs) of muscle- and
neuronal-type nicotinic acetylcholine receptors (nAChRs) (reviewed
in [1]). The muscle-type nAChR, in particular the nAChR isolated from
Torpedo californica electric organ, has been studied extensively over
the past several decades and serves as the archetype of the Cys-loop
ligand-gated ion channel superfamily. This genetically linked receptor
superfamily includes both muscle- and neuronal-type nAChRs, type A
and C γ-aminobutyric acid, type 3 5-hydroxytryptamine (serotonin),
and glycine receptors (reviewed in [2–4]).
Previous studies from our laboratory determined the molecular
mechanisms underlying the noncompetitive inhibition of AChRs1 623 572 3550.
.
ll rights reserved.elicited by tricyclic antidepressants (TCAs) [5]. These earlier studies
further established that imipramine inhibits the binding of the well-
characterized NCA [piperidyl-3, 4-3H(N)]-(N-(1-(2 thienyl)cyclo-
hexyl)-3,4-piperidine) ([3H]TCP), a structural and functional analog
of the dissociative anesthetic phencyclidine (PCP), to both resting and
desensitized nAChRs (Kis=6.7±0.4 and 0.75±0.04 μM, respectively
[5]). However, the structural components of the TCA binding sites in
conformationally distinct nAChRs have not been characterized in
detail. Thus, to further characterize the TCA binding sites, we have
employed [3H]2-azidoimipramine (see Fig. 1), a photoreactive analog
of imipramine, to covalently tag the TCA binding sites in the Torpedo
nAChR ion channel.We choose the Torpedo nAChR as a receptor model
mainly because of its high abundance in the electroplaque tissue of
T. californica ﬁsh compared to cells and neurons expressing neuronal-
type nAChRs.
The radioligand binding, photoafﬁnity labeling, and docking and
molecular dynamics data suggest that imipramine interacts with the
PCP binding sites in the resting (closed) and desensitized states. More
speciﬁcally, imipramine binds mainly to the M2 transmembrane
segment of the Torpedo AChR, which is the principal segment forming
Fig. 1.Molecular structure of [3H]2-azidoimipramine. The molecule was built using the
Builder module of Insight 2005L (Accelrys, San Diego, CA), and is rendered as a space-
ﬁlling surface (CPK). The nitrogen atoms from the azido group are colored in blue.
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modeling of the TCA binding site on neuronal nAChRs.
2. Materials and methods
2.1. Materials
[3H]2-azidoimipramine (Fig. 1) (5H-Dibenz(b,f)azepine-5-propa-
namine, 2-azido-10,11-dihydro-N,N-dimethyl-) (80 Ci/mmol) was
synthesized according to Rotman and Pribluda [6] by American
Radiolabeled Chemicals (St. Louis, MO). [Benzene ring-3H(N)]-imi-
pramine hydrochloride ([3H]imipramine) (41.3 Ci/mmol) and [piper-
idyl-3,4-3H(N)]-(N-(1-(2 thienyl)cyclohexyl)-3,4-piperidine) ([3H]
TCP) (45 Ci/mmol) were purchased from PerkinElmer Life Sciences
Products, Inc. (Boston, MA). Radiolabeled drugs were stored in
ethanol at −20 °C. Carbamylcholine hydrochloride (Carb), suberyldi-
choline dihydrochloride, l-[l-(2-thienyl)cyclohexyl]pyrrolidine (TCP),
imipramine hydrochloride, α-bungarotoxin (α-BgTx), polyethyleni-
mine, and Tricine were purchased from Sigma-Aldrich (St. Louis,
MO). Phencyclidine hydrochloride (PCP) was obtained through the
National Institute on Drug Abuse (NIDA) (NIH, Bethesda, Maryland).
Staphylococcus aureus glutamyl endopeptidase (V8 protease) was
obtained from MP Biochemicals (Irvine, CA), and Genapol C-100 from
Calbiochem (San Diego, CA). Triﬂuoroacetic acid (TFA) and [1-
(dimethylamino) naphtalene-5-sulfonamido]ethyltrimethylammo-
nium perchlorate (dansyltrimethylamine) were purchased from Pierce
(Rockford, IL). Prestained low range molecular weight standards were
purchased from Life Technologies, Inc. (Gaithersburg, MD).
2.2. Preparation of nAChR-rich membranes and afﬁnity-puriﬁed nAChRs
reconstituted in lipid vesicles
nAChR-rich membranes were isolated from frozen T. californica
electric organs obtained from Aquatic Research Consultants (San
Pedro, CA) by differential and sucrose density gradient centrifuga-
tion, as described previously [7]. The ﬁnal membrane suspensions in
∼38% sucrose were stored at −80 °C. Total AChR membrane protein
was determined using the bicinchoninic acid (BCA) protein assay
(Pierce Chemical Co., Rockford, IL). Speciﬁc activities of these mem-
brane preparations were determined by the decrease in dansyl-
trimethylamine (6.6 μM) ﬂuorescence produced by the titration ofsuberyldicholine into receptor suspensions (0.3 mg/ml) in the
presence of 100 μM PCP. The activities ranged from 0.9 to
1.2 nmol of suberyldicholine binding sites/mg total protein (0.45–
0.60 nmol AChR/mg protein). Fluorescence titrations were carried
out in 5-mm quartz cuvettes using an Olis DM245 spectroﬂuori-
meter (Bogart, GA). Dansyltrimethylamine excitation and emission
wavelengths were 295 and 546 nm, respectively. To reduce stray-
light effects, a 530 nm cutoff ﬁlter was placed in the path of the
emission wavelength.
nAChRs were afﬁnity-puriﬁed using a bromoacetylcholine bro-
mide-derivatized Afﬁ-Gel 10 column (Bio-Rad) as described pre-
viously [8]. Brieﬂy, the afﬁnity column was prepared by coupling
50 mL of Afﬁ-gel 10 to cystamine, reduction of the cystamine
disulphide, and then sulfhydryl coupling to bromoacetylcholine
bromide (1.5 g). The column was then equilibrated with ∼15 column
volumes of lipid (asolectin, a crude soybean lipid extract) in 1% cholate
in vesicle dialysis buffer (VDB) (100 mM NaCl, 0.1 mM EDTA, 0.02%
NaN3, 10 mM MOPS, pH 7.4) (0.2 mL/min; N15 h). The solubilized
material was slowly applied to the afﬁnity column (0.3 mL/min, ∼24 h,
at 4 °C). The columnwas thenwashed extensively with asolectin–lipid
solution (0.2–0.9 mg/mL lipid) in 1% cholate in VDB (15 column
volumes; N15 h). This extensive wash ensures complete exchange of
endogenous lipids for the asolectin–lipid mixture [8]. nAChRs were
eluted from the column using the asolectin–lipid solution (0.2 mg/mL)
containing 10 mM carbamylcholine (Carb). Peak protein fractions
(A280×0.6; see Ref. [8]) were pooled and the lipid–protein molar ratio
adjusted to 400 to 1 except were speciﬁed. To remove Carb and
reconstitute nAChRs into membranes containing asolectin–lipid,
pooled fractions were dialyzed against 2 L of VDB (4 d with buffer
change once every day). The reconstituted nAChRs were aliquoted
(0.25 mg per tube) and stored at −80 °C.
2.3. Imipramine- and PCP-induced inhibition of [3H]imipramine binding
to nAChR in different conformational states
We studied the effect of imipramine and PCP on maximal [3H]
imipramine binding to the Torpedo nAChR. In this regard, nAChR
native membranes (0.3 μM nAChR) were suspended in binding saline
buffer (50 mM Tris–HCl, 120 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM
MgCl2, pH 7.4), with 10 nM [3H]Imipramine in the presence of 1 mM
Carb (desensitized state), or alternatively with 75 nM [3H]Imipra-
mine in the presence of 1 μM α-bungarotoxin [α-BgTx; resting
(closed) state], and preincubated for 30 min at room temperature
(RT). α-Bungarotoxin is a competitive antagonist that maintains the
nAChR in the resting (closed) state [9]. Since imipramine inhibits
[3H]TCP binding to nAChRs in the resting (closed) (∼6 μM) and
desensitized (∼0.7 μM) states [5], the nonspeciﬁc binding for the
imipramine-induced inhibition of [3H]imipramine binding experi-
ments was determined in the presence of 100 μM (desensitized) or
500 μM imipramine (resting/closed), respectively. For the PCP-
induced inhibition of [3H]imipramine binding experiments, the
nonspeciﬁc binding was determined in the presence of 50 μM
(desensitized) or 100 μM PCP (resting/closed) according to Arias et al.
[10]. The total volume was divided into aliquots, and increasing
concentrations of imipramine or PCP (i.e., 0.1 nM–500 μM) were
added to each tube and incubated for 2 h at RT. nAChR-bound
radioligand was then separated from free ligand by a ﬁltration assay
using a 48-sample harvester system with GF/B Whatman ﬁlters
(Brandel Inc., Gaithersburg, MD), previously soaked with 0.5%
polyethylenimine for 30 min. The membrane-containing ﬁlters
were transferred to scintillation vials with 3 mL of Bio-Safe II
(Research Product International Corp, Mount Prospect, IL), and the
radioactivity was determined using a Beckman SL6500 scintillation
counter (Beckman Coulter, Inc., Fullerton, CA).
The concentration–response data were curve-ﬁtted by nonlinear
least-squares analysis using the Prism software (GraphPad Software,
Table 1
Afﬁnity of phencyclidine and imipramine for the [3H]imipramine binding site in the
resting (closed) and desensitized nAChRs
NCA Desensitized state Resting state
Ki, μMa nHb Ki, μMa nHb
PCP 0.41±0.02 1.15±0.05 1.2±0.3 0.80±0.10
Imipramine 0.85±0.05 0.96±0.05 3.8±0.4 0.82±0.08
Data obtained from the plots of Fig. 2.
a Inhibition constant.
b Hill coefﬁcient.
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the Hill equation:
θ = 1= 1 + L½ =IC50ð ÞnH
  ð1Þ
where θ is the fractional amount of the radioligand bound in the
presence of inhibitor at a concentration [L] compared to the amount of
the radioligand bound in the absence of inhibitor (total binding). IC50
is the inhibitor concentration at which θ=0.5 (50% bound), and nH is
the Hill coefﬁcient. The nH values were summarized in Table 1.
The observed IC50 values from the competition experiments
described above were transformed into inhibition constant (Ki) values
using the Cheng–Prusoff relationship [11]:
Ki = IC50= 1 +
3H
h i
imipramine
h i
=K imipramined
 n o
ð2Þ
where [[3H]imipramine] is the initial concentration of [3H]imipramine
and Kdimipramine is the dissociation constant for [3H]imipramine (0.7 μM
in the desensitized state and 6.4 μM in the resting (closed) state [5]).
The calculated Ki values for imipramine and PCP were summarized in
Table 1.
2.4. Photolabeling of Torpedo nAChRs with [3H]2-azidoimipramine
Afﬁnity-puriﬁed Torpedo nAChRs reconstituted in asolectin–lipid
membranes were adjusted to 0.25 mg/mL in VDB and supplemented
with 1.1 mM oxidized glutathione to serve as an aqueous scavenger.
Membrane aliquots (0.25mg analytical scale; 12 mg preparative scale)
were then incubated with [3H]2-azidoimipramine (from an ethanolic
stock solution; ﬁnal concentrations are 0.174 μM and b1% ethanol)
either in the presence of 400 μM Carb (desensitized state) or 2 μM α-
BgTx (resting/closed state). The total volume was divided in different
glass test tubes in absence (total photolabeling) or in the presence of
50 μM TCP (nonspeciﬁc photolabeling). After 1 h in the dark at RT,
samples were irradiated at 312 nm (Spectroline EN-280L, Spectronics,
Westbury, NY) for 10 min at a distance of b1 cm. Photolyzed
membrane suspensions were then pelleted, solubilized in electro-
phoresis sample buffer, and subjected to SDS-PAGE.
2.5. SDS-polyacrylamide gel electrophoresis
SDS-PAGEwas performed according to themethod of Laemmli [12]
with analytical (1.0 mm thick) and preparative (1.5 mm) separating
gels comprised of 8% polyacrylamide/0.33% bis-acrylamide. Following
electrophoresis, nAChR subunits were visualized by staining with
Coomassie Blue R-250 [0.25% (w/v) in 45% methanol, 10% acetic acid,
45% distilled water] and destaining (25% methanol, 10% acetic acid,
65% distilled water). For ﬂuorography, stained gels were impregnated
with ﬂuor (Amplify; GE Biosciences, Piscataway, NJ) for 30 min, dried
and exposed at −80 °C to Eastman Kodak X-Omat LS ﬁlm (typical
exposure time=2–4 weeks). 3H incorporation into individual poly-
peptides was also quantiﬁed by liquid scintillation counting of excised
gel slices [13]. For either analytical or preparative [3H]2-azidoimipra-
mine photolabeling experiments, nAChRα-subunits were fragmented
by limited “in gel” digestion with S. aureus V8 protease [13–15].
Following electrophoresis, stained 8% acrylamide gels were soaked in
distilled water overnight and nAChR α-subunit band from each
labeling conditions [+/− Carb, +/+ Carb and TCP in the desensitized
state; and − and + α-BgTx in the resting (closed) state] were excised
and transferred directly to thewell(s) of either a 1.0 mm (analytical) or
1.5 mm (preparative) thick mapping gel, composed of a 5-cm-long
4.5% acrylamide stacking gel and a 11-cm-long 15% acrylamide
separating gel. For analytical labelings, each gel slice was overlaid
with 6 μg S. aureus V8 protease in overlay buffer (5% sucrose, 125 mM
Tris–HCl, 0.1% SDS, pH 6.8) and electrophoresed at 60 V constant
voltage for ∼3 h and then at ∼6 mA constant current overnight. AfterCoomassie Blue R-250 staining (1 h) and destaining (2–3 h), the
analytical gels were impregnated with ﬂuor, dried and exposed to ﬁlm
(up to 12 weeks). Preparative 8% acrylamide gels (1.5 mm thick) were
soaked in distilled water overnight and the nAChR α−subunit excised
as a strip (∼15 cm). The gel strip was transferred to 15% acrylamide
mapping gel and overlaid with 250 μg V8 protease in overlay buffer.
Following electrophoresis, staining, and soaking in distilled water
overnight, the following subunit proteolytic fragment band was
excised: αV8-20 (αSer173-Glu338; using the nomenclature of Blanton
and Cohen [16]). The excised proteolytic fragment was then isolated
by passive diffusion into 25 mL of elution buffer [0.1 M NH4HCO3, 0.1%
(w/v) SDS, 1% β-mercaptoethanol, pH 7.8] for 4 days at RT with gentle
shaking [16]. The gel suspensions were then ﬁltered (Whatman N
1 paper) and concentrated using Centriprep-10 concentrators (10 kDa
cutoff, Amicon, Billerica, MA). Excess SDS was removed by acetone
precipitation (N85% acetone at −20 °C overnight).
2.6. Proteolytic digestions
For digestion with Endoproteinase Lys-C (EndoLys-C), acetone
precipitated V8 protease subunit fragments from each condition
were resuspended in 200 μL of 15 mM Tris, 0.1% (w/v) SDS, pH 8.1,
and then incubated with EndoLys-C (1.5 U in 100 μL EKC buffer) for
5–7 h at RT. Aliquots (∼10%) of each EKC digest were resolved on an
analytical Tricine SDS-PAGE gels and processed for ﬂuorography (up
to 10 weeks exposure). The bulk of the material from each EKC digest
was separated on individual preparative scale (1.0 mm thick) Tricine
SDS-PAGE gels. Following staining and destaining of each preparative
Tricine gel, selected fragments were excised based upon the results
of ﬂuorographs of analytical Tricine gels and with the aid of low
range molecular weight standards. The selected 11 kDa (αEKC-11)
and 6 kDa (αEKC-6) fragments were then isolated by passive elution
into 5 mL of elution buffer over 4 days at RT. The gel suspensions
were ﬁltered, concentrated (Centriprep-3, Amicon), and further
puriﬁed by rpHPLC.
2.7. HPLC puriﬁcation
Proteolytic fragments of the nAChR α-subunit were puriﬁed by
rpHPLC on a Shimadzu LC-10A binary HPLC system, using a
Brownlee Aquapore C4 column (100×2.1 mm). Solvent A was
0.08% triﬂuoroacetic acid (TFA) in water and Solvent B was 0.05%
TFA in 60% acetonitrile/40% 2-propanol. A nonlinear elution gradient
at 0.2 mL/min was employed (25% to 100% Solvent B in 100 min)
and fractions were collected every 2.5 min (42 fractions/run). The
elution of peptides was monitored by absorbance at 210 nm. 50 μL
aliquots of each collected fraction were counted for radioactivity
using liquid scintillation counting.
2.8. Sequence analysis
Amino terminal sequence analysis was performed on a Beckman
Instruments (Porton) 20/20 automated protein sequencer using gas
phase cycles (Texas Tech Biotechnology Core Facility). Pooled HPLC
Fig. 2. (A) Imipramine- and (B) PCP-induced inhibition of [3H]imipramine binding to
desensitized (○) and resting (closed) (□) nAChRs. nAChR-rich membranes (0.3 μM
nAChR) were equilibrated (2 h) with [3H]imipramine (75 nM in the resting (closed) state
and 10 nM in the desensitized state) and carbamylcholine (1 mM) or α-BgTx (1 μM), in
the presence of increasing concentrations of imipramine or PCP (i.e., 0.1 nM–500 μM).
The nAChR membranes were then ﬁltered and the radioactivity of the ﬁlters was
measured as described under “Materials and methods”. For experiments in (A), the
nonspeciﬁc radioactivity was determined with 100 (desensitized state) or 500 μM
imipramine (resting state). For experiments in (B), the nonspeciﬁc radioactivity was
determined with 50 (desensitized state) or 100 μM PCP (resting state). Shown is the
mean±SD of two experiments performed in triplicate. The IC50 and nH values were
obtained by nonlinear least-squares ﬁt according to Eq. (1). The Ki values for imipramine
and PCP were calculated using the Cheng–Prusoff relationship [Eq. (2)].
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centrifugation, resuspended in 20 μL 0.1% SDS and immobilized on
chemically modiﬁed glass ﬁber disks (Beckman Instruments), which
were used to improve the sequencing yields of hydrophobic peptides.
Peptides were subjected to at least 10 sequencing cycles.
2.9. Docking and molecular dynamics of imipramine and PCP in the
nAChR ion channel
The membrane domain of the nAChR is formed by 20 α-helical
transmembrane segments, where each subunit incorporates four
segments (M1, M2, M3 and M4). The M2 segments are relatively
amphiphilic and are exposed to the centrally located pore permeable
to water and cations. Since the numbering of amino acid residues
varies greatly between members of the Cys-loop superfamily, the
residues in M2 of nAChR subunits are referred to here using the prime
nomenclature (1′ to 20′), corresponding to residues Met243 to Glu262
in the Torpedo nAChR α-subunit. As a target for modeling the binding
of imipramine and PCP in the present study we used a structural
model of the pore region of nAChR based on the cryo-electron
microscopy structure of the Torpedo nAChR at ∼4 Å resolution [17,18]
(PDB ID 2BG9).
Computational simulations were divided into three steps. In the
ﬁrst step, imipramine and PCP molecules were prepared using
HyperChem 6.0 (HyperCube Inc., Gainesville, FL). Sketched molecules
were optimized using the semiempirical method AM1 (Polak-Ribiere
algorithm to a gradient lower than 0.1 kcal/Å/mol) and then
transferred to the second step: ligand docking. The Molegro Virtual
Docker (MVD 2008.2.4.0 Molegro ApS Aarhus, Denmark) was used
for docking simulations of ﬂexible ligands into the rigid target nAChR
model. In this step the complete 2BG9 structure was used [17,18].
The docking space was limited and centered on the middle of the ion
channel and extended enough to ensure covering of the whole
channel domain for sampling simulations (docking space was
deﬁned as a sphere of 21 Å in diameter). The actual docking
simulations (settings: numbers of runs=100; maximal number of
interactions=10,000; maximal number of poses=10) were per-
formed and the pose representing the lowest value of the scoring
function (MolDockScore) for each ligand was selected for further
simulations. In the next step, molecular dynamics were performed
using the Yasara 6.10.18 package (Yasara Biosciences, Graz, Austria).
Complexes of 2BG9 with imipramine or PCP were edited to provide
coordinates for the membrane domain only. For each subunit, M1–
M4 transmembrane helices plus connecting loops were left in the
system, all other parts of the protein were removed. Thus, we
obtained two models representing complexes between the nAChR
channel domain and imipramine or PCP. These models were further
inserted into periodic boxes (88 Å×88 Å×68 Å), solvated with water
molecules using Yasara default algorithm and ﬁxing constrains for
backbone atoms were assigned. In all further simulations the
AMBER99 force ﬁeld for both protein and ligand structures was
used (Yasara BioSciences) with the cutoff 7.86 Å and particle-mesh
Ewald longrange function for electrostatic interactions. The initial
complexes were pre-optimized with steepest descent method fol-
lowed by 500 steps of simulated annealing. Finally, the actual 0.8 ns
molecular dynamics was performed using the following parameters:
temperature=298 K; multiple timesteps=1 fs for intramolecular
and 2 fs for intermolecular forces, PressureControl — waterprobe
(0.99 g/ml) ensemble. Snapshots of the simulations were saved every
5 ps.
Results of dynamics simulations were characterized by calcula-
tion of the binding energy deﬁned here as the difference between
the energy of the complete complex system and a summation
of energy of the ligand and the energy of the hydrated protein
alone. All these calculations were performed with the same force
ﬁeld settings.3. Results
3.1. Imipramine- and PCP-induced inhibition of [3H]imipramine binding
to the resting (closed) and desensitized nAChRs
To further localize the site of interaction of ADs and to determine
the relative associative properties of TCAs in different conformational
states of the nAChR, the PCP- and imipramine-induced inhibition of
[3H]imipramine binding to Torpedo nAChRswas examined (Fig. 2). The
high concentrations of Torpedo nAChRs in these native membrane
provides a high level of speciﬁc [3H]imipramine binding which cannot
be obtained with cells (or cell membranes) expressing neuronal
nAChRs. Experiments were carried out in the presence of 1 mM Carb
(desensitized state) or 1 μM α-BgTx (resting/closed state).
The results show that imipramine (Fig. 2A) and PCP (Fig. 2B)
completely eliminate speciﬁc [3H]imipramine binding to the nAChR in
a concentration-dependent fashion in either the desensitized or the
resting (closed) state. From these experiments, we obtained the
respective imipramine and PCP IC50 values, which were transformed
to absolute Ki values according to the Cheng–Prusoff equation [Eq.
(2)]. The imipramine Ki values were 0.85±0.05 and 3.8±0.4 μM in the
desensitized and resting (closed) state, respectively (see Table 1).
Therefore, it seems likely that imipramine binds with ∼5-fold higher
afﬁnity to the desensitized nAChR than to the resting (closed) nAChR.
These values are nearly identical to those obtained by [3H]TCP
competition experiments (∼0.7 and ∼6.4 μM, respectively; [5]). The
observed nH values were close to unity (see Table 1), indicating that
the binding is noncooperative, and thus, suggesting the existence of a
single imipramine binding site on each conformational state.
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nAChR in a steric fashion, we had suggested that the imipramine
binding site overlaps the PCP locus in the resting (closed) and
desensitized states [5]. Supporting this conclusion is the fact that the
calculated PCP Ki values in the desensitized (0.41±0.02 μM) and
resting (closed) (1.2±0.3 μM) states (see Table 1) are practically the
same as those previously determined in the desensitized (∼0.25 μM;
[19]) and in the resting (closed) (∼0.83 μM; [10]) state, respectively.
Further, from these results, and considering that the observed nH
values are close to unity (1.15±0.05 in the desensitized state, and 0.80±
0.10 in the resting (closed) state; see Table 1), we can conclude that PCP
displaces [3H]imipramine from its high-afﬁnity binding site in a
mutually exclusive (steric) manner when the receptor is in either the
desensitized or resting (closed) state. Thus, it is likely that the locus for
TCAs overlaps, at least partially, the PCP binding site in both states.
3.2. Photoincorporation of [3H]2-azidoimipramine into nAChR subunits
Initial photolabeling experiments with [3H]2-azidoimipramine
(Fig.1) were designed to characterize the extent of photoincoproration
into nAChR subunits in either the desensitized (in the presence of
400 μM Carb) or resting (closed) state (in the presence of 2 μM α-
BgTx), as well as to assess how the addition of TCP affects the extent of
[3H]2-azidoimipramine photoincorporation into nAChR subunits.
Afﬁnity-puriﬁed nAChRs were utilized for [3H]2-azidoimipramine
photolabeling experiments in order to accurately assess the extent of
subunit labeling without the confusion of potential labeling of non-
AChR polypeptides present in nAChR-rich membranes. These afﬁnity-
puriﬁed nAChRs (reconstituted in asolectin–lipid vesicles) are func-
tionally indistinguishable from receptors present in native nAChR-rich
Torpedo membranes [8]. For labelings in the absence of agonist, α-
BgTx was added to stabilize the resting (closed) state [9]. Afﬁnity-
puriﬁed nAChRs reconstituted in asolectin–lipid membranes
(0.25 mg/ml) were supplemented with 1.1 mM oxidized glutathioneFig. 3. Photoincorporation of [3H]2-azidoimipramine into Torpedo nAChRs in the desensit
azidoimipramine in the presence of carbamylcholine (Carb) (+/− lane) and in presence of Carb
irradiation, polypeptides were resolved by SDS-PAGE and processed for ﬂuorography (4 wee
and δ). (B) The extent of [3H]2-azidoimipramine photoincorporation into nAChR subunits in
[3H]2-azidoimipramine-labeled nAChR subunit bands were excised from the dried 8% acr
scintillation counting. The amount of [3H]2-azidoimipramine photoincorporation intoα, β, γ
(results from three separate photolabeling experiments produced qualitatively similar resu(aqueous scavenger) and equilibrated with 0.174 μM [3H]2-azidoimi-
pramine either in the presence of Carb, both Carb and TCP, or α-BgTx.
After UV-light irradiation, nAChRs subunits were separated by SDS-
PAGE, and the extent of photoincorporation of [3H]2-azidoimipramine
into each nAChR subunit was monitored by ﬂuorography following
electrophoresis. A representative ﬂuorograph of an 8% polyacrylamide
gel (Fig. 3A) demonstrates that there is appreciable photoincorpora-
tion of [3H]2-azidoimipramine into individual nAChR subunits either
in the presence of Carb (+/− lane) or in the presence of both Carb and
TCP (+/+ lane). The overall labeling pattern and the relative
incorporation of [3H]2-azidoimipramine into individual nAChR sub-
units were clearly reduced by the inclusion of TCP, indicating that this
photolabeling is TCP-sensitive (analytical labelings were repeated at
least three times with nearly identical results). For photolabeling
experiments conducted in the absence of agonist, where the receptor
is mainly in the resting (closed) state, the photoincorporation of [3H]2-
azidoimipramine into α-subunits is signiﬁcantly reduced by ∼50%
(see Fig. 4B) in the presence ofα-BgTx (themajority of receptors are in
the resting/closed state), whereas the extent of photolabeling in the
other subunits is not signiﬁcantly affected (b10%). Further addition of
TCP had no effect on the extent of [3H]2-azidoimipramine incorpora-
tion into any subunit (data not shown). These result suggests that
there is minimal speciﬁc [3H]2-azidoimipramine photolabeling in the
resting (closed) state. The α-BgTx-sensitive labeling in the α-subunit
is best explained by [3H]2-azidoimipramine photoincorporation into
residues within the agonist binding sites and thus, this labeling is
eliminated when the agonist binding sites are occupied by α-BgTx.
To quantify the extent of photoincorporation into each nAChR
subunit (in the presence of Carb, as well as both Carb and TCP) the
gel bands were excised from the 8% acrylamide gel and the
radioactivity was measured in a scintillation counter. Based on
liquid scintillation counting of excised gel bands, [3H]2-azidoimipra-
mine incorporates into each nAChR subunit, with approximately 25%
(n=3) of the total subunit labeling inhibited by addition of TCP (seeized state. (A) Afﬁnity-puriﬁed nAChRs were equilibrated (1 h) with 0.174 μM [3H]2-
and TCP (+/+ lane), and then irradiated at 312 nm for 10min at a distance of b1 cm. After
ks exposure). Indicated on the left are the mobility of Torpedo nAChR subunits (α, β, γ,
the presence of Carb (closed bars) and in the presence of Carb and TCP (open bars). The
ylamide gel and the 3H-radioactivity associated with each band was determined by
, and δ subunits, inhibited by the addition of TCP was 24%, 23%,18%, and 18%, respectively
lts).
Fig. 4. (A) Photoincorporation of [3H]2-azidoimipramine into Torpedo nAChRs in the resting (closed) state. Afﬁnity-puriﬁed nAChRs were equilibrated (1 h) with 0.174 μM [3H]2-
azidoimipramine in the absence (− lane) and in presence of α-BgTx (+ lane), and then irradiated at 312 nm for 10 min at a distance of b1 cm. After irradiation, polypeptides were
resolved by SDS-PAGE and processed for ﬂuorography (4 weeks exposure). The [3H]2-azidoimipramine-labeled nAChR subunit bands were excised from the dried 8% acrylamide gel
and the 3H-radioactivity associated with each band was determined by scintillation counting. (B) The amount of [3H]2-azidoimipramine photoincorporation into the α−subunit
inhibited by the addition of α-BgTx was 54%. Labeling in the β, γ, δ-subunits was not signiﬁcantly (b10%) affected.
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imipramine to the nAChR, the lipophilicity of imipramine, as well
as other factors, the presence of a signiﬁcant level of nonspeciﬁc [3H]
2-azidoimipramine incorporation is by no means unexpected.Fig. 5. Proteolytic mapping of the site of [3H]2-azidoimipramine incorporation into the
nAChR α-subunit in the desensitized state using “in gel” digestion with S. aureus V8
protease. Afﬁnity-puriﬁed nAChRs were labeled with 0.174 μM [3H]2-azidoimipramine
in the presence of Carb (+/− lane) and in presence of Carb and TCP (+/+ lane). After
photolysis (312 nm for 10 min), peptides were resolved by SDS-PAGE (1.0 mm thick, 8%
acrylamide). nAChR subunit bands were excised following identiﬁcation by staining
(Coomassie Blue) and transferred to the wells of a 15% acrylamide mapping gel for ‘in
gel’ digestion with S. aureus V8 protease. Following electrophoresis, the mapping gel
was stained with Coomassie Blue, destained and processed for Fluorography (12 week
exposure). The principal [3H]2-azidoimipramine-labeled proteolytic fragment was
αV8-20.The site(s) of [3H]2-azidoimipramine photoincorporation into the
nAChR α-subunit labeled in the presence of Carb, both Carb and TCP
(Fig. 3), and α-BgTx (Fig. 4), were initially mapped by proteolytic
digestion. The α-subunit from each condition was partially digestedFig. 6. Proteolytic mapping of the site of [3H]2-azidoimipramine incorporation into the
nAChR α-subunit in the resting (closed) state using “in gel” digestion with S. aureus V8
protease. Afﬁnity-puriﬁed nAChRs were labeled with 0.174 μM [3H]2-azidoimipramine
in the absence (− lane) and in the presence of α-BgTx (+ lane). After photolysis (312 nm
for 10 min), peptides were resolved by SDS-PAGE (1.0 mm thick, 8% acrylamide). nAChR
subunit bands were excised following identiﬁcation by staining (Coomassie Blue) and
transferred to the wells of a 15% acrylamide mapping gel for ‘in gel’ digestion with S.
aureus V8 protease. Following electrophoresis, the mapping gel was stained with
Coomassie Blue, destained and processed for Fluorography (12 week exposure). The
[3H]2-azidoimipramine labeling on the principal proteolytic fragment,αV8-20, was lost
in the presence of α-BgTx.
Fig. 8. Reversed-phase HPLC puriﬁcation of [3H]2-azidoimipramine-labeled fragments
from EKC digests of αV8-20. The [3H]2-azidoimipramine-labeled 11 kDa (Panel A) and
6 kDa (Panel B) fragments isolated from exhaustive EKC digests of αV8-20 (see Fig. 6)
were resolved by rpHPLC on a Brownlee Aquapore C4 column as described in the
“Materials and methods”. The elution of peptides was monitored by absorbance at
210 nm and elution of 3H by scintillation counting of aliquots (50 μL) of each 500 μL
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Photoincorporation in the α-subunit was found to be restricted to
one principal V8 protease fragment, αV8-20 (Ser173-Glu338) (Figs. 5
and 6). The stretch of the primary sequence of the α-subunit
contained within the V8 protease fragment V8-20 includes the
transmembrane segments M1, M2, and M3. This result indicates that
[3H]2-azidoimipramine photoincorporates into a 20 kDa proteolytic
fragment of the α-subunit in presence of Carb (+/− lane; Fig. 5) and
that the labeling is signiﬁcantly reduced by the addition of TCP (+/+
lane; Fig. 5).
The site(s) of [3H]2-azidoimipramine photoincorporation into the
nAChR α-subunit labeled in the absence of Carb, and in the presence
of α-BgTx (Fig. 4), were also mapped by ‘in gel’ digestion with V8
protease and found to be restricted to the αV8-20 fragment (Fig. 6).
That α-BgTx essentially eliminated [3H]2-azidoimipramine photo-
incorporation into αV8-20 is best explained by two possibilities: [3H]
2-azidoimipramine photolabeling is lost when the ion channel is in
the resting (closed) conformational state or [3H]2-azidoimipramine
photolabeling of the α-subunit is largely restricted to the agonist
binding site (in particular Loop C).
In order to further localize the site(s) of TCP-sensitive [3H]2-
azidoimipramine photoincorporation within the α-subunit when the
receptor is in the desensitized state, labeled αV8-20 was digested in
solution with EndoLys-C. Digestion of αV8-20 with EndoLys-C is
known to generate fragments of approximately 11 and 6 kDa starting
at αMet243 (the N-terminus of αM2) and at αHis186 (that contains the
agonist binding site Loop C; [7]), respectively. When aliquots of the
EndoLys-C digestion of [3H]2-azidoimipramine-labeled αV8-20 were
resolved by Tricine SDS-PAGE, two labeled fragments were visualized
by ﬂuorography with a principal band migrating at an apparent
molecular weight of 11 kDa and a minor band migrating at 6 kDa
(Fig. 7). The bulk of each digest was puriﬁed by rpHPLC (Fig. 8). When
the EndoLys-C digests of [3H]2-aziodimipramine-labeled 11 kDa and
6 kDa fragments were fractionated by HPLC, there was a broad 3H-
peak for the fragments labeled in the presence of Carb, whereas theFig. 7. Endoproteinase Lys-C digestion of [3H]2-azidoimipramine-labeled V8 protease
fragment αV8-20. The V8 protease fragment αV8-20, isolated from nAChRs labeled
with 0.174 μM [3H]2-azidoimipramine in the presence of Carb (+/− lane) and in presence
of Carb and TCP (+/+ lane), were exhaustively digested with Endoproteinase Lys-C (EKC,
1.5 U per 100 μl EKC buffer) for 5–7 days at RT. Aliquots of the total digests (∼10%) were
fractionated by Tricine SDS-PAGE and then subjected to ﬂuorography for 10 weeks. The
principal band of 3H evident in EKC digest migrates with an apparent molecular mass of
∼11 kDa (αEKC11) and minor band at ∼6 kDa (αEKC6).
fraction in presence of Carb (●) and in presence of Carb and TCP (○). On the basis of
recovery of radioactivity, N90% of the material was recovered from the rpHPLC column.
HPLC fractions 37–39 (A) or 34–36 (B) were pooled and subjected to 10 automated
protein sequencing cycles.3H-radioactivity was signiﬁcantly reduced in those fractions from the
sample labeled in the presence of Carb and TCP. The fractions 37 to 39
(Fig. 8A) and 34 to 36 (Fig. 8B) were pooled for the digests of 11 kDa
and 6 kDa, respectively, and subjected to 10 automated protein
sequencing cycles. For each fragment, sequence analysis revealed the
presence of a primary peptide beginning at Met243 (11 kDa fragment)
and His186 (6 kDa fragment). Based on the apparentmolecular weights
of 11 and 6 kDa, estimated from the Tricine gel, the 11 kDa peptide
begins at Met243 and would extend to the end of the αV8-20 (Glu338)
fragment and includes both the M2 and M3 transmembrane
segments. The 6 kDa fragment begins at His186 and extends through
the transmembrane segmentM1 (Arg209-Tyr234) and terminates at the
beginning of the M2 segment (Lys242). Unfortunately, the extent of
[3H]2-azidoimipramine incorporation into the M1, M2, and M3
segments was too low to effectively allow for the determination of
individually labeled amino acids by amino terminal radio-sequence
analysis. Nonetheless, these results suggest that [3H]2-azidoimipra-
mine labels amino acids primarily within the M2 segment with minor
labeling in the M1 segment of theα-subunit when the nAChR is in the
desensitized state.
3.3. Docking and molecular dynamics of imipramine and PCP in the
nAChR ion channel
In the present study, molecular modeling was used to build and
optimize molecular models of the nAChR ion pore in complex with
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series of docking poses and ranked them using energy-based
criterion using the embedded scoring function in MolDockScore.Based on this ranking, the lowest energy pose of the ligand–receptor
complex can be selected. The MolDockScore value for the PCP best
ranked complex was −77.31 kJ/mol. This pose is shown in Fig. 9C.
The molecule interacts with the middle section of the ion channel in
the cavity formed between the serine (position 6′) and valine rings
(position 13′) (Fig. 9C). Analysis of the complex shows that the
docked molecule interacts only with all ﬁve M2 helices, provided by
each subunit. A very similar mode of binding was observed in
previous simulations where the PCP molecule was docked into the
channel models of α3β4 [21] and α3β2 [22] nAChR. In contrast, in
an earlier docking study using the α7 nAChR as a model [23], PCP
mainly bound in a region deeper in the ion channel located between
positions 2′ and 6′.
Fig. 9A and B show the results of analogous docking of imipramine
molecule. In this case the lowest energy of the complex was −100.68
kJ/mol, suggesting that the modeled binding should be higher for
imipramine than for PCP. Generally, the orientation of the imipramine
within the channel is similar to that observed for PCP. The imipramine
lowest energy pose is located in the middle portion of the channel, in
the cavity formed between the serine (position 6′) and valine (position
13′) rings. Molecule location allows interaction with each of the M2
helices and, as in the case of PCP docking, there is no evidence
suggesting interactions with transmembrane helices other than M2.
When best scored complexes (this time systems were limited to
membrane domain of the receptor as described in Materials and
methods section) were hydrated with explicit waters, optimized, and
simulated with molecular dynamics at 298 K for 0.8 ns, the PCP
molecule did not signiﬁcantly changed the position comparing to the
starting pose (mean RMSD from starting position=1.89 Å). PCP
interacted exclusively with nearby pore-lining residues at over-
lapping sites between the serine (position 6′) and valine rings
(position 13′), without interacting with the external mouth of the ion
channel, which is located beyond position 13′, closer to the
extracellular ring (position 29′). In comparison to the PCP simula-
tions, molecular dynamics of the imipramine-nAChR complex
showed more signiﬁcant changes compared to the starting position
(mean RMSD value=3.23 Å). The imipramine molecule reoriented
signiﬁcantly during the period of simulation (0.8 ns), which was
reﬂected by a greater RMSD value. Nevertheless, the molecule still
interacted predominantly with residues between positions 6′ and 13′
within the ion channel. Carried simulation did not indicate any
possibility of ligand interacting with transmembrane helices other
than M2.
Amber ForceField allowed to estimate the ligand binding energy
(deﬁned here as the difference between the energy of the complete
complex system and a summation of the energy of the ligand and
the energy of the hydrated protein alone). Comparison of these
values for both analyzed ligands suggest a similar binding energy for
imipramine in complex with the nAChR ion channel (−35.2±3.8 kcal/
mol) compared to that for PCP (−29.9±2.4 kcal/mol). Binding energy
estimations indicate that afﬁnities of both NCAs are quite similar,
which is consistent with the Ki values determined experimentally
(see Table 1).Fig. 9. Lowest energy complexes of imipramine (A and B) and PCP (C) docked into the
Torpedo nAChR model (2BG9.pdb) [17]. The complexes are shown with the δ subunit
removed for clarity. The order of the remaining subunits are (from left to right): α, γ, α
and β. (A) Transversal view of the AChR ion channel showing the location of the
imipramine binding site. The AChR is rendered in secondary structure mode and the
ligand is rendered in CPK model. (B and C) Detailed view of imipramine (B) and PCP
(C) interacting within the ion channel between the valine (position 13′) and serine
(position 6′) rings. The target protein is rendered in semitransparent surface with
visible secondary structure. Explicit CPK atoms of residues forming the valine (green)
and serine (red) rings. The ligands are rendered in stick mode with hydrogen atoms not
shown explicitly.
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The principal goal of this work was to structurally characterize the
TCA binding sites on the Torpedo muscle-type nAChR in the
desensitized and resting (closed) states. To this end, receptor state-
dependent radioligand competition binding, photoafﬁnity labeling,
and docking and molecular dynamics experiments were performed.
We used different experimental strategies to identify the TCA binding
sites. First, we calculated the Ki and nH values of imipramine and PCP
displacement of [3H]imipramine binding to the nAChR as a comple-
ment to previously published results demonstrating mutually exclu-
sive binding of [3H]TCP and imipramine [5]. These results serve to
localize the TCA site within the pore of the ion channel in the
desensitized and resting (closed) conformational states. Second, we
used [3H]2-azidoimipramine, a photoactivatable analog of imipra-
mine, to directly identify the TCA binding domains in the nAChR.
Finally, we performed docking and molecular dynamics of the Torpedo
nAChR ion channel complexed with imipramine or PCP to support our
experimental data.
We ﬁrst estimated that imipramine binds the Torpedo AChR with
∼5-fold higher afﬁnity to the desensitized state compared to the
resting (closed) state by [3H]imipramine competition experiments
(see Table 1). This is in accord with previous competition experiments
where imipramine inhibits [3H]TCP binding to the desensitized nAChR
with ∼10-fold higher afﬁnity than to the resting (closed) nAChR [5].
The result from these experiments suggests that TCAs speciﬁcally
displace [3H]TCP from its high-afﬁnity site in a mutually exclusive
manner in either the resting (closed) or desensitized state. Comple-
mentary results indicate that PCP completely inhibits [3H]imipramine
binding to nAChRs in both states in a concentration-dependent
manner (see Table 1). In fact, Schild-type analyses indicate that
imipramine-induced inhibition of [3H]TCP binding to the nAChR in
each conformational state is mediated by steric mechanisms [24].
These results support our hypothesis that the TCA binding site
overlaps the PCP locus in each conformational state [5,25]. The exact
location for the PCP site is still not ﬁrmly established (reviewed in
[1,25]). Many lines of indirect evidence support a single site for PCP
(one on each conformational state) within the ion channel of the
muscle-type nAChR [10,26–28]. In the resting (closed) nAChR, the PCP
site has been located between the valine ring (position 13′) and the
extracellular ring (position 29′) [10,28,29] (reviewed in [1,25]).
Whereas in the desensitized state, the PCP binding site is located
closer to the middle of the ion channel [19,30] (reviewed in [1,25]).
The results from the second set of experiments demonstrate that
[3H]2-azidoimipramine photoincorporates into each nAChR subunit
in the presence of Carb (desensitized state) with approximately 25%
of the labeling inhibitable by addition of TCP (speciﬁc labeling). In
contrast, TCP has no signiﬁcant effect on the extent of labeling in the
resting (closed) state (data not shown). The lack of any detectable
TCP-inhibitable [3H]2-azidoimipramine photoincorporation in the α-
subunit in the presence of α-BgTx (resting/closed state) is in accord
with the radioligand binding results indicating that the imipramine
binding afﬁnity to the resting (closed) nAChR is 5–10 times lower
than that in the desensitized state (see Table 1 and Refs. [5,24]). The
fact that TCP, the structural and functional analog of PCP, inhibits
[3H]2-azidoimipramine photoincorporation in the desensitized state
supports the conclusion, obtained by radioligand binding competi-
tion experiments (see Fig. 2, Table 1, and Refs. [5,24]), that both
imipramine and PCP bind to overlapping sites within the ion channel
(see previous paragraph).
In the desensitized state, the majority of the speciﬁc 3H-labeling
within the α-subunit maps the transmembrane segment M2
(although the possibility that speciﬁc [3H]2-azidoimipramine labeling
resides within the M3 segment cannot be excluded), suggesting that
imipramine binds primarily within the ion channel of the receptor. A
small amount of TCP-inhibitable [3H]2-azidoimipramine labelingmapped to the M1 transmembrane segment. Whether this labeling
represents an additional binding site or labeling of the M1 segment
from within the pore of the ion channel has yet to be established. In
this regard, previous photolabeling experiments using [3H]ethidium
diazide as a probe for the PCP site, showed that, in addition to residues
at the M2 transmembrane segment, amino acids at the M1
transmembrane segment were labeled [30]. However, our dynamics
studies do not support the possibility that PCP or imipramine interacts
with other transmembrane segments than M2 (see Fig. 9).
The photolabeling and radioligand binding results obtained
experimentally are consistent with the data from our docking and
molecular dynamics experiments (Fig. 9). We began simulations with
docking of imipramine and PCP molecules into the ion pore. Whenwe
applied molecular dynamics simulations to lowest docked energy
poses, both ligands sampled overlapping siteswithin a strip of residues
into the ionpore. Fig. 9A andB show that imipramineﬁts nicely into the
ion pore in a domain comprising valine (position 13′) and serine
(position 6′) rings. This result is in contrast to an earlier studyon theα7
nAChR [23] inwhich PCP bound deeper in the ion channel, proximal to
the two serine rings located at position 2′ and 6′, respectively. On the
other hand, Fig. 1 shows that the two positive charges on imipramine
are shielded within the center of the molecule and distributed as
partial atomic charges overmany atoms. As a result, strong short-range
electrostatic interactions are prevented. This effect is in contrast to our
previous studies with adamantane-amine derivatives in which the
single positive chargewas exposed on the surface of themolecule [10].
It is interesting that we observed overlapping binding sites for
imipramine when the lumen of the ion channel was kept relatively
constant by tethering the backbone atoms of the M2α-helices to their
position in the nAChR template (PDB ID 2BG9) [17]. There is general
agreement that the structure of the ion channel will change during the
transitions between the resting (closed) and desensitized states
[18,31,32], and recent molecular dynamics studies of nAChR [33] and
the ion channel from the homologous glycine receptor [34] have
revealed unexpectedly large ﬂuctuations of the dimensions of the ion
pore. These large ﬂuctuations are consistent with the signiﬁcant
experimental differences in [3H]2-azidoimipramine labeling between
the resting (closed) and desensitized states.
Since the Torpedo nAChR remains the prototype for the study of
all members of the Cys-loop ligand-gated ion channel superfamily, it
may be possible that ADs inhibit neuronal nAChRs by mechanisms
similar to the ones described for the muscle nAChR [5]. Studies of
ACh-current generated by rat neuronal α2β4 and mouse muscle-
type nAChRs expressed in Xenopus laevis oocytes showed that
imipramine inhibits both types of nAChRs with similar potency and
through similar mechanisms [35].
As was outlined above, both muscle- and neuronal-type nAChRs
have homologous structures. Therefore, the evidence presented here
may help to further determine the primary structural components of
TCA binding sites on the muscle-type as well as neuronal-type
nAChRs. We plan to further examine the contribution of α1 M2 and
M1 amino acids to imipramine binding and pharmacological action,
speciﬁcally by site-directed mutagenic amino acid substitutions and
electrophysiological recordings to asses the effect of imipramine on
receptor function.
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